NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
Rhea-AI Summary
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, will release its Q2 2025 financial results on August 14, 2025, after market close.
The company will host a conference call at 4:30 PM ET to discuss corporate updates, financial performance, recent regulatory events, and operational plans. Investors can access the call via webcast on the company's website or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).
Positive
- None.
Negative
- None.
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day.
The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
| For further information: | |
| Matthew Duffy | Brian Korb |
| Co-CEO, Hope Therapeutics, Inc. | Managing Partner, astr Partners |
| Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 |
| mduffy@nrxpharma.com | brian.korb@astrpartners.com |
FAQ
When will NRx Pharmaceuticals (NRXP) report Q2 2025 earnings?
How can investors access NRXP's Q2 2025 earnings call?
What topics will be covered in NRXP's Q2 2025 earnings call?
Where can investors find NRXP's Q2 2025 earnings press release?
